ESR1 and breast carcinoma: NEO-201 was also observed to bind to 50% of breast cancer cell lines expressing either the estrogen receptor (ER) or the progesterone receptor (PR), whether alone or in combination with HER2 and to 75% of the HER2+ cell lines.